Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 11Neoplasms, Plasma Cell 3Recurrence 1Plasmacytoma 1Paraproteinemias 1Neoplasms 1Immunoglobulin Light-chain Amyloidosis 1Hematologic Diseases 1Corneal Diseases 1Blood Protein Disorders 1

Interventions

Dexamethasone 3isatuximab 2Lenalidomide 2pomalidomide 1daratumumab 1Ranitidine 1Diphenhydramine 1Cyclophosphamide 1Bortezomib 1Acetaminophen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Paraproteinemias × daratumumab × Clear all
NCT05280275 2023-12-01

A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Transplant Ineligible

Hellenic Society of Hematology

Phase 1/2 Unknown
36 enrolled
Plasma cell

Blood Protein Disorders, Corneal Diseases, Hematologic Diseases, Multiple Myeloma, Neoplasms, Paraproteinemias, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡